INS and type 1 diabetes mellitus: Considering the current issues of high cost and low availability and their off-label status, widespread use of GLP-1RAs and novel coagonists along with insulin in people with T1D cannot be routinely recommended at present but may play a role in future treatment concepts once outcome trials are available (378).